Fate Therapeutics (FATE) PT Raised to $7 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Fate Therapeutics (FATE) PT Lowered to $6 at H.C. Wainwright Following FDA Clearing of FATE-NK100
March 20, 2017 7:36 AM EDTH.C. Wainwright lowered its price target on Fate Therapeutics (NASDAQ: FATE) to $6.00 (from $8.00) while maintaining a Buy rating following the FDA clearing of the Investigational New Drug application (IND) for FATE-NK100. Analysts expect preliminary data from the Phase 1/2 PROTECT study of Fate's lead product candidate ProTmune in mid-2017.
Analyst Shaunak Deepak commented, "With FDA clearing the Investigational New Drug application (IND) for FATE-NK100, we believe Fate made considerable progress to... More
Fate Therapeutics (FATE) Sees Strong Mid-Day Gains Amid Bullish Analyst PT Hikes
March 17, 2017 1:35 PM EDTFate Therapeutics (NASDAQ: FATE) sees intra-day momentum following earlier bullish analyst calls following results after the close and into a data-rich year ahead. BMO nearly doubled its price target to $7. Shares of FATE are up 6% on volume that is running 2x the norm.
... More